Gastrointestinal Infections

A study shows countries with the highest income levels had greater vaccine protection against rotavirus gastroenteritis (RVGE).

Experts discuss the bacteria’s transmission in the community setting, how to reduce disease and economic burdens, and ways to improve quality of life for patients.

Recommendations for treating C. difficile upon a first recurrence as well as following multiple recurrences based on currently available treatment options and recommendations by the IDSA/SHEA clinical practice guidelines.

A panel of clinicians recognize the challenges associated with screening patients for the C. difficile infection and highlight factors that should prompt someone for an evaluation.

Types of testing algorithms used in clinical practice to help clarify a diagnosis of C. difficile infection.

Important things to understand about diagnosing C. difficile and recommendations for properly differentiating the condition from other diseases when working-up a patient.

A discussion regarding the increasing frequency of C. difficile recurrence and its effects on patients and the healthcare system.

Sources of transmission and challenges that impact the management of community-onset C. difficile.

What healthcare providers need to know about the 2 strains of C. difficile, including types of patients impacted and typical outcomes.

Understanding the burden of C. difficile across the United States, panelists explore common risk factors associated with the condition and discuss the different ways it can manifest in patients.

Biologics have become a novel treatment in recurrent C. difficile.

Community-acquired infections—including those associated with outpatient settings—are still problematic, authors say.

Results from England’s first licensed FMT stool bank are now available.

An electronic alert that aids in diagnostic stewardship may be helpful in reducing inappropriate testing for C diff, according to a new study.

Using enteral vancomycin for C diff prophylaxis may be the key to reducing morbidity and improving outcomes in pediatric and young adult recipients of HSCT.

Mark Riddle, MD, DrPH, speaks to Contagion at ACG 2019 about the results of a study looking into microbiome changes associated with single-dose antibiotics for the treatment of traveler's diarrhea.

Rebiotix has announced that it has completed enrollment of a phase 3 clinical trial for RBX2660.